AR056908A1 - THE OLIGONUCLEOTIDES AND ITS USES - Google Patents
THE OLIGONUCLEOTIDES AND ITS USESInfo
- Publication number
- AR056908A1 AR056908A1 ARP050104073A AR056908A1 AR 056908 A1 AR056908 A1 AR 056908A1 AR P050104073 A ARP050104073 A AR P050104073A AR 056908 A1 AR056908 A1 AR 056908A1
- Authority
- AR
- Argentina
- Prior art keywords
- bone
- oligonucleotides
- osteogenesis
- animal
- area
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 4
- 210000000988 bone and bone Anatomy 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 230000011164 ossification Effects 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000002188 osteogenic effect Effects 0.000 abstract 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000003239 periodontal effect Effects 0.000 abstract 1
- 230000009897 systematic effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se presentan oligonucleotidos con capacidad para disimular la osteogénesis en animales vertebrados, inclusive en pacientes humanos. Estos oligonucleotidos osteogénicos pueden ser utilizados en una amplia gama de procedimientos clínicos para reemplazar y restituir defectos oseos y periodontales, o para facilitar el implante exitoso de protesis y los procedimientos de distraccion en huesos. Esta invencion proporciona métodos para la generacion de hueso en un área de un animal que presenta deficiencia de tejido esquelético. Estos consisten en la administracion local o sistemática en el animal de una composicion que consiste en uno o más oligonucleotidos osteogénicos, en un vehículo farmacéuticamente aceptable. La composicion es administrada en una entidad efectiva para inducir la osteogénesis en el área del hueso. Reivindicacion 1: Uso de un oligonucleotido compuesto de unos 14 a 100 nucleotidos para la elaboracion de un medicamento destinado a inducir la osteogénesis.Oligonucleotides are presented with the ability to disguise osteogenesis in vertebrate animals, including in human patients. These osteogenic oligonucleotides can be used in a wide range of clinical procedures to replace and restore bone and periodontal defects, or to facilitate successful implantation of prostheses and bone distraction procedures. This invention provides methods for the generation of bone in an area of an animal that has skeletal tissue deficiency. These consist of the local or systematic administration in the animal of a composition consisting of one or more osteogenic oligonucleotides, in a pharmaceutically acceptable carrier. The composition is administered in an effective entity to induce osteogenesis in the bone area. Claim 1: Use of an oligonucleotide composed of about 14 to 100 nucleotides for the preparation of a medicament intended to induce osteogenesis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP050104073 AR056908A1 (en) | 2005-09-27 | 2005-09-27 | THE OLIGONUCLEOTIDES AND ITS USES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP050104073 AR056908A1 (en) | 2005-09-27 | 2005-09-27 | THE OLIGONUCLEOTIDES AND ITS USES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056908A1 true AR056908A1 (en) | 2007-11-07 |
Family
ID=38734789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104073 AR056908A1 (en) | 2005-09-27 | 2005-09-27 | THE OLIGONUCLEOTIDES AND ITS USES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR056908A1 (en) |
-
2005
- 2005-09-27 AR ARP050104073 patent/AR056908A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058359A1 (en) | COMBINATIONS | |
| CY1121447T1 (en) | COMPOSITIONS FOR INCREASING TELEVISION ACTIVITY | |
| ATE374597T1 (en) | MICROBALLS FOR ACTIVE EMBOLIZATION | |
| AR024516A1 (en) | BI-AROMATIC COMPOUNDS ANALOGS OF VITAMIN D, ITS USE, PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITION THAT INCLUDE AT LEAST ONE OF SUCH COMPOUNDS AND USE OF SUCH COSMETIC COMPOSITION. | |
| DE60028666D1 (en) | Use of adipose-derived stromal cells for differentiation into chondrocytes and their use to repair cartilage tissue | |
| Huang et al. | Low-level diode laser therapy reduces lipopolysaccharide (LPS)-induced bone cell inflammation | |
| BRPI0512583A (en) | compositions and methods of producing same, releasing active agent into and through the epidermis tissue of a person or animal and treating a patient suffering from onychomycosis, nail psoriasis and infections | |
| Moslemi et al. | Outcomes of alveolar ridge preservation with recombinant human bone morphogenetic protein-2: a systematic review | |
| Pabst et al. | Influence of porcine-derived collagen matrix on endothelial progenitor cells: an in vitro study | |
| Yudell et al. | Bone gap healing in the dog using recombinant human bone morphogenetic protein-2 | |
| WO2004087065A3 (en) | Compositions for induction of a therapeutic response | |
| ITFI20030058A1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING THIAZOLIDINEDIONI | |
| BR0313954A (en) | Biocompatibly ceramic composition, medical device, method for fabricating a biocompatibly ceramic composition, medical and orthopedic implants, dental filler or dental implant, drug vehicle for drug delivery in a patient's body, use of biocompatibly ceramic composition, method for generating in vivo heat in a patient's body for therapeutic purposes, and therapeutic method | |
| AR044200A1 (en) | COMPOSITION OF FONDAPARINUX SODICO DE HIGH PURITY, A PROCEDURE FOR THE PREPARATION OF THIS COMPOSITION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT AS AN ACTIVE PRINCIPLE | |
| TW200633978A (en) | 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists | |
| ES2244361T1 (en) | USE OF THE ANECORTAVE ACETATE FOR THE PROTECTION OF VISUAL ACUTE IN PATIENTS WITH MACULAR DEGENERATION ASSOCIATED WITH AGE. | |
| BRPI0407178A (en) | Osteogenic Pharmaceutical Composition | |
| ES2167853T3 (en) | N-ARIL 2-HYDROXY RENTED. | |
| DE60031016D1 (en) | Use of antiseptics for the preparation of medicaments for the prophylaxis and treatment of inflammation in the interior of the human body | |
| AR056908A1 (en) | THE OLIGONUCLEOTIDES AND ITS USES | |
| BR0315609A (en) | Method of treating, preventing, modifying or controlling pain and pharmaceutical composition | |
| RU2005131578A (en) | APLIDINE FOR TREATMENT OF MULTIPLE MYELOMA | |
| ECSP034632A (en) | USE OF 6-DIMETILAMINOMETIL-1-FENIL-CICLOHEXACO SUBSTITUTED COMPOUNDS IN URINARY INCONTINENCE THERAPY | |
| Mainard | Sustitutos óseos | |
| Wu et al. | Interdisciplinary management of mandibular intraosseous haemagioma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |